You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,730,876


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,730,876
Title:Synthesis of a compound that modulates kinases
Abstract: The present disclosure provides processes for the preparation of a compound of formula I: ##STR00001## or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.
Inventor(s): Ibrahim; Prabha N. (Mountain View, CA), Jin; Masayoshi (Tokyo, JP), Matsuura; Shinji (Tokyo, JP)
Assignee: Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)
Application Number:16/510,617
Patent Claims: 1. A crystalline form of a compound of formula II: ##STR00048## prepared by a process comprising: (1) adding the compound of formula II to from about 0.4% v/v wet methyl tert-butyl ether to about 1.5% v/v wet methyl tert-butyl ether to provide a reaction mixture; (2) refluxing the reaction mixture; (3) cooling the reaction mixture to about room temperature; and (4) isolating the crystalline form of the compound of formula II from the reaction mixture.

2. The crystalline form of the compound of formula II according to claim 1, wherein step (1) comprises adding the compound of formula II to about 0.5% v/v wet methyl tert-butyl ether to provide the reaction mixture.

3. The crystalline form of the compound of formula II according to claim 2, wherein step (2) further comprises heating the reaction mixture to a temperature of about 52-53.degree. C.

4. The crystalline form of the compound of formula II according to claim 3, wherein the crystalline form of compound II is characterized by an X-ray powder diffractogram (XRPD) comprising peaks (.+-.0.2.degree.) at 7.1, 16.5, 20.8, 23.2 and 28.1 .degree.2.theta. as determined on a diffractometer using Cu-Ka radiation.

5. The crystalline form of the compound of formula II according to claim 1, wherein the crystalline form of compound II is characterized by an X-ray powder diffractogram (XRPD) comprising peaks (.+-.0.2.degree.) at 7.1, 16.5, 20.8, 23.2 and 28.1 .degree.2.theta. as determined on a diffractometer using Cu-Ka radiation.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.